Switzerland is a key hub for biomanufacturing, with immunological products like antibodies
and vaccines making up 18.5% of 2024 exports. Swiss companies drive biotech innovation and biocatalysis
across sectors globally, extending the traditional focus on pharmaceuticals to fine chemicals, fragrances
and food tech. The development is supported by national collaborations and international coalitions.
Tubulis secures €308m in record-breaking Series C financing
Latest NewsMunich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.
Blood test detects pancreatic cancer early
Latest NewsMainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved 100% sensitivity and 95% specificity in a feasibility study. The results suggest the test could detect cancer—and even precancerous lesions—earlier than current methods.
AstraZeneca agrees to MFN price reductions with US government
Latest NewsUK-based AstraZeneca plc has become the second of 17 pharmaceutical companies, after Pfizer Inc., to accept U.S. President Donald Trump’s proposal to voluntarily lower drug prices and move production to the United States. In return, the company will benefit from a three-year exemption from U.S. import tariffs on prescription drugs manufactured outside the country.
BioSpain 2025: “Building European biotech resilience”
Latest News, OpinionAt BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions.
Tackling 5 Key Challenges in Annex 11 and MHRA Readiness
slider, Sponsored PublicationsDownload the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies across multiple European sites and jurisdictions.
Novo buys again: 5-billion-dollar deal for Akero´s MASH
Latest NewsNovo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their footprint.
New CEO strengthens management
AppointmentsFairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.
Opportunity Health SL wins start-up pitch contest
BackgroundOut of 43 pitches, the founders of Spanish Opportunity Health S.L. delivered the best presentation for a new life sciences product: a choking device that can potentially be used by anyone in emergency situations without the need for external assistance.
Panel discussion: what drives US investments?
BackgroundAlongside a start-up pitch featuring 45 international participants, the second day of BioSpain 2025 (7–9 October 2025, Barcelona) offered biotech start-ups a panel discussion with prominent US investors, who shared their selection criteria and outlined the impact of the current geopolitical situation on investment decisions.
Biomanufacturing in Switzerland
BackgroundSwitzerland is a key hub for biomanufacturing, with immunological products like antibodies
and vaccines making up 18.5% of 2024 exports. Swiss companies drive biotech innovation and biocatalysis
across sectors globally, extending the traditional focus on pharmaceuticals to fine chemicals, fragrances
and food tech. The development is supported by national collaborations and international coalitions.